Transmission-blocking activity of antibodies to Plasmodium falciparum GLURP.10C chimeric protein formulated in different adjuvants

scientific article

Transmission-blocking activity of antibodies to Plasmodium falciparum GLURP.10C chimeric protein formulated in different adjuvants is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1007018875
P356DOI10.1186/S12936-015-0972-0
P932PMC publication ID4640242
P698PubMed publication ID26552428
P5875ResearchGate publication ID283740945

P50authorMarga van de Vegte-BolmerQ45380602
Michael TheisenQ58310143
Robert SauerweinQ72530989
Will RoeffenQ72536015
P2093author name stringMichael Christiansen
Shrawan Kumar Singh
Theo Arens
Swarnendu Kaviraj
Gorm Andersen
GeertJan van Gemert
Laxman Sevargave
P2860cites workA malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparumQ24814432
The dynamics of naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs230 & Pfs48/45 in a low endemic area in TanzaniaQ28744581
A central role for P48/45 in malaria parasite male gamete fertilityQ30043154
A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodiesQ33198902
Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.Q33350210
A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coliQ33485233
A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African childrenQ33987686
From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.Q35809113
Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquitoQ36351262
NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infectionsQ36547334
Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in miceQ36670217
Surface antigens of Plasmodium falciparum gametocytes--a new class of transmission-blocking vaccine targets?Q37487002
Adjuvants for malaria vaccinesQ37582428
Reduced antibody responses against Plasmodium falciparum vaccine candidate antigens in the presence of Trichuris trichiuraQ38995073
Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidateQ38995083
A Plasmodium falciparum 48/45 single epitope R0.6C subunit protein elicits high levels of transmission blocking antibodiesQ39467691
A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stagesQ39520295
Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsionQ39812986
Measurement by membrane feeding of reduction in Plasmodium falciparum transmission induced by endemic seraQ40959724
Plasmodium falciparum: heterologous synthesis of the transmission-blocking vaccine candidate Pfs48/45 in recombinant vaccinia virus-infected cellsQ41003251
Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, GabonQ41877888
Infectivity of cultured Plasmodium falciparum gametocytes to mosquitoesQ41946006
Association between anti-Pfs48/45 reactivity and P. falciparum transmission-blocking activity in sera from CameroonQ44137386
Plasmodium falciparum: membrane feeding assays and competition ELISAs for the measurement of transmission reduction in sera from CameroonQ44140956
Transmission blocking malaria vaccinesQ44145217
Plasmodium falciparum transmission blocking monoclonal antibodies recognize monovalently expressed epitopesQ44146493
Changes in Anopheles funestus biting behavior following universal coverage of long-lasting insecticidal nets in BeninQ44165680
Epitope analysis of the malaria surface antigen pfs48/45 identifies a subdomain that elicits transmission blocking antibodies.Q47829675
Immunological properties of recombinant proteins of the transmission blocking vaccine candidate, Pfs48/45, of the human malaria parasite Plasmodium falciparum produced in Escherichia coli.Q47837358
Assembly and expression of a synthetic gene encoding the antigen Pfs48/45 of the human malaria parasite Plasmodium falciparum in yeastQ47857505
A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2--a GLURP-MSP3 fusion protein malaria vaccine candidateQ47973517
Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trialQ48034345
Cloning and expression of the gene coding for the transmission blocking target antigen Pfs48/45 of Plasmodium falciparumQ48103837
Plasmodium falciparum: production and characterization of rat monoclonal antibodies specific for the sexual-stage Pfs48/45 antigenQ73509627
P921main subjectPlasmodium falciparumQ311383
P304page(s)443
P577publication date2015-11-09
P1433published inMalaria JournalQ15749954
P1476titleTransmission-blocking activity of antibodies to Plasmodium falciparum GLURP.10C chimeric protein formulated in different adjuvants
P478volume14

Reverse relations

cites work (P2860)
Q91723010A Plant-Produced in vivo deglycosylated full-length Pfs48/45 as a Transmission-Blocking Vaccine Candidate against malaria
Q37736878A review on Lactococcus lactis: from food to factory
Q36906995Analysis of the dose-dependent stage-specific in vitro efficacy of a multi-stage malaria vaccine candidate cocktail
Q40110842Antibody responses to two new Lactococcus lactis-produced recombinant Pfs48/45 and Pfs230 proteins increase with age in malaria patients living in the Central Region of Ghana
Q40212118Carbohydrate fatty acid monosulphate esters are safe and effective adjuvants for humoral responses
Q96813794Comparison of carrier proteins to conjugate malaria transmission blocking vaccine antigens, Pfs25 and Pfs230
Q33750638Construct design, production, and characterization of Plasmodium falciparum 48/45 R0.6C subunit protein produced in Lactococcus lactis as candidate vaccine
Q40159945Expression, Purification and Characterization of GMZ2'.10C, a Complex Disulphide-Bonded Fusion Protein Vaccine Candidate against the Asexual and Sexual Life-Stages of the Malaria-Causing Plasmodium falciparum Parasite
Q28365035Functional characterization of Plasmodium berghei PSOP25 during ookinete development and as a malaria transmission-blocking vaccine candidate
Q92001627Immunity against sexual stage Plasmodium falciparum and Plasmodium vivax parasites
Q47137421In Silico Validation of D7 Salivary Protein-derived B- and T-cell Epitopes of Aedes aegypti as Potential Vaccine to Prevent Transmission of Flaviviruses and Togaviruses to Humans
Q47251697Protein-protein conjugate nanoparticles for malaria antigen delivery and enhanced immunogenicity
Q90101806Statistical Methods for Standard Membrane-Feeding Assays to Measure Transmission Blocking or Reducing Activity in Malaria
Q38775588Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine

Search more.